Rachel Ryu

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Topics

Systematic Review

Oral Anticoagulants

Aortic Valve Replacement

Venous Thromboembolism

Top Venues

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Cardiology research

Medical sciences (Basel, Switzerland)

Circulation. Cardiovascular quality and outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Rachel Ryu, Khaled Bahjri, Huyentran Tran
Potential Association of Holidays on Internationalized Normalized Ratio in Warfarin-Users at a Multidisciplinary Clinic. Cardiology research 14 (1) (2023)
Rachel Ryu, Khaled Bahjri, Huyentran Tran
Potential Association of Holidays on Internationalized Normalized Ratio in Warfarin-Users at a Multidisciplinary Clinic. Cardiology research 14 (1) (2023)
Rachel Ryu
DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban). Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 28 (2022)
Rachel Ryu
DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban). Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 28 (2022)
Rachel Ryu, Rebecca Tran
DOACs in Mechanical and Bioprosthetic Heart Valves: A Narrative Review of Emerging Data and Future Directions. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 28 (2022)
Rachel Ryu
DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban). Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 28 (2022)
Rachel Ryu
DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban). Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 28 (2022)
Rachel Ryu, Christopher Hauschild, Khaled Bahjri, Huyentran Tran
The Usage of Concomitant Beta-Blockers with Vasopressors and Inotropes in Cardiogenic Shock. Medical sciences (Basel, Switzerland) 10 (4) (2022)
Mohammed Shurrab, Rachel Ryu, Cynthia A Jackevicius
Off-Label Direct Oral Anticoagulant Dosing: Caution Advised. Circulation. Cardiovascular quality and outcomes 14 (12) (2021)
Anitha Saravanakumar, Armin Sadighi, Rachel Ryu, Fatemeh Akhlaghi
Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016. Clinical pharmacokinetics 58 (10) (2020)